Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12854029 | 0.83 | PTGS1 (0.64) | PTGS2PTGS1PDPK1 | |
| SCHEMBL3470729 | 0.80 | PTGS1 (0.53) | PTGS2PTGS1PDPK1 | |
| SCHEMBL12978932 | 0.79 | PTGS2 (0.71) | PTGS2PTGS1PDPK1 | |
| SCHEMBL12854023 | 0.78 | PTGS1 (0.73) | PTGS2PTGS1PDPK1 | |
| SCHEMBL27716920 | 0.78 | PTGS2 (0.58) | PTGS2PTGS1PDPK1 | |
| SCHEMBL3472108 | 0.77 | PTGS1 (0.49) | PTGS2PTGS1PDPK1 | |
| SCHEMBL3472834 | 0.76 | PDPK1 (0.66) | PTGS2PTGS1PDPK1 | |
| SCHEMBL3472443 | 0.76 | PTGS2 (0.62) | PTGS2PTGS1PDPK1 | |
| SCHEMBL3474106 | 0.75 | RXRA (0.56) | PTGS2PTGS1 | |
| SCHEMBL21935294 | 0.75 | KLKB1 (0.53) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| CN-101248048-B | Imidazole based LXR modulators | EXELIXIS INC | 2013-08-28 | — | — | CN | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| CN-101248048-A | Imidazole based LXR modulators | EXELIXIS INC (US) | 2008-08-20 | — | — | CN | disclosed |
| EP-1910307-A1 | PYRAZOLE BASED LXR MODULATORS | Exelixis, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007002559-A1 | PYRAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002559-A1 | PYRAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331295-A1 | MODULATORS OF LXR | NR1H2, NR1H3, NR1H4 | PTGS2 1500/4885PTGS1 803/4885PDPK1 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.